If a company's history and track record were good enough reasons to buy its shares, it'd be easy to make a case for investing in Abbott Laboratories (NYSE: ABT). Abbott is a longtime leader in the ...

Since my previous article, shares of Abbott Laboratories have returned 10 ... It's just not up to par with what I would need to see to maintain my buy rating. I would need to see a pullback to ...

Analyst Larry Biegelsen from Wells Fargo maintained a Buy rating on Abbott Laboratories (ABT – Research Report) and keeping the price target at $133.00. Larry Biegelsen has given his Buy rating ...

The ABBOTT PRISM system is intended for in vitro diagnostic use only. A high throughput, highly automated test system for blood screening: The ABBOTT PRISM is a fully automated, high-volume blood ...

Citi reaffirmed its positive stance on Abbott Laboratories (NYSE:ABT), maintaining a Buy rating and a price target of $127.00. The endorsement follows updates from the company's management ...

Bernstein analyst Lee Hambright maintained a Buy rating on Abbott Laboratories (ABT – Research Report) yesterday and set a price target of $138.00. Lee Hambright has given his Buy rating due to ...

Abbott has a diversified business, exciting growth avenues, and a strong dividend program. The company faces potential obstacles, including legal problems and stiff competition. However, that's no ...

Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported. Abbott appears a compelling earnings-beat candidate. However, investors should pay ...